Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men
Journal of Cachexia, Sarcopenia and Muscle · 2024-12 · 15 (6) · 2476-2486
DOI: 10.1002/jcsm.13582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 04.09.2024. Verfasst von Je Hyun Seo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Health Service Medical Center, Veterans Medical Research Institute, Seoul, South Korea. Hauptthemen laut MEDLINE: Sarcopenia, Sphingolipids, Biomarkers. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asan Institute for Life Sciences, Ministry of Science and ICT, South Korea, Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
Background
Sarcopenia is an age‐related progressive loss of muscle mass and function. Sarcopenia is a multifactorial disorder, including metabolic disturbance; therefore, metabolites may be used as circulating biomarkers for sarcopenia. We aimed to investigate potential biomarkers of sarcopenia using metabolomics.
Methods
After non‐targeted metabolome profiling of plasma from mice of an aging mouse model of sarcopenia, sphingolipid metabolites and muscle cells from the animal model were evaluated using targeted metabolome profiling. The associations between sphingolipid metabolites identified from mouse and cell studies and sarcopenia status were assessed in men in an age‐matched discovery (72 cases and 72 controls) and validation (36 cases and 128 controls) cohort; women with sarcopenia (36 cases and 36 controls) were also included as a discovery cohort.
Results
Both non‐targeted and targeted metabolome profiling in the experimental studies showed an association between sphingolipid metabolites, including ceramides (CERs) and sphingomyelins (SMs), and sarcopenia. Plasma SM (16:0), CER (24:1), and SM (24:1) levels in men with sarcopenia were significantly higher in the discovery cohort than in the controls (all P < 0.05). There were no significant differences in plasma sphingolipid levels for women with or without sarcopenia. In men in the discovery cohort, an area under the receiver‐operating characteristic curve (AUROC) of SM (16:0) for low muscle strength and low muscle mass was 0.600 (95% confidence interval [CI]: 0.501–0.699) and 0.647 (95% CI: 0.557–0.737). The AUROC (95% CI) of CER (24:1) and SM (24:1) for low muscle mass in men was 0.669 (95% CI: 0.581–0.757) and 0.670 (95% CI: 0.582–0.759), respectively. Using a regression equation combining CER (24:1) and SM (16:0) levels, a sphingolipid (SphL) score was calculated; an AUROC of the SphL score for sarcopenia was 0.712 (95% CI: 0.626–0.798). The addition of the SphL score to HGS significantly improved the AUC from 0.646 (95% CI: 0.575–0.717; HGS only) to 0.751 (95% CI: 0.671–0.831, P = 0.002; HGS + SphL) in the discovery cohort. The predictive ability of the SphL score for sarcopenia was confirmed in the validation cohort (AUROC = 0.695, 95% CI: 0.591–0.799).
Conclusions
SM (16:0), reflecting low muscle strength, and CER (24:1) and SM (16:0), reflecting low muscle mass, are potential circulating biomarkers for sarcopenia in men. Further research on sphingolipid metabolites is required to confirm these results and provide additional insights into the metabolomic changes relevant to the pathogenesis and diagnosis of sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Veterans Health Service Medical Center, Veterans Medical Research Institute, Seoul, South Korea.
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea.
- Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Orthopedic Surgery, Seoul Now Hospital, Anyang, South Korea.
- Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
ORCID-Profile: Seung Hun Lee
Förderung
- Asan Institute for Life Sciences
- Ministry of Science and ICT, South Korea
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Seo, J. H., Koh, J. M., Cho, H. J., Kim, H., Lee, Y. S., Kim, S. J., Yoon, P. W., Kim, W., Bae, S. J., Kim, H. K., Yoo, H. J., & Lee, S. H. (2024). Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men. Journal of Cachexia, Sarcopenia and Muscle, 15(6), 2476-2486. https://doi.org/10.1002/jcsm.13582
Vancouver
Seo JH, Koh JM, Cho HJ, Kim H, Lee YS, Kim SJ, et al. Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(6):2476-2486. doi:10.1002/jcsm.13582
BibTeX
@article{Seo2024,
author = {Seo, Je Hyun and Koh, Jung-Min and Cho, Han Jin and Kim, Hanjun and Lee, Young-Sun and Kim, Su Jung and Yoon, Pil Whan and Kim, Won and Bae, Sung Jin and Kim, Hong-Kyu and Yoo, Hyun Ju and Lee, Seung Hun},
title = {Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
volume = {15},
number = {6},
pages = {2476--2486},
doi = {10.1002/jcsm.13582}
}
EUVIMED